GlassScriptPhysician profile
Lauralee Sibiga
NPI 1710311923
$3,946.37
in general payments reported to CMS, 2019-2025
32 companies · $401 in 2025
The $401 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,396 · 2022: $1,006 · 2023: $631 · 2024: $512 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,544.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $532.89 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $493.15 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $382.72 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $319.27 | 2021-2024 | |
| Amgen INC. | $247.88 | 2021-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $197.17 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $189.64 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.01 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $180.13 | 2021-2025 | Airsupra |
| Grifols USA, LLC | $139.02 | 2021-2024 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $126.80 | 2021-2024 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $101.75 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $90.27 | 2021-2023 | Gardasil 9, Verquvo, Vaxneuvance |
| Biohaven Pharmaceuticals, INC. | $84.80 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.62 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $71.39 | 2021-2022 | |
| Glaxosmithkline, LLC. | $67.00 | 2021-2025 | Shingrix |
| Astellas Pharma US INC | $66.41 | 2021 | |
| Sunovion Pharmaceuticals INC. | $66.16 | 2021 | |
| Abbott Laboratories | $62.40 | 2023-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.80 | 2021 | |
| Phathom Pharmaceuticals, INC. | $29.36 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $27.73 | 2021-2024 | Gvoke Hypopen |
| Almatica Pharma LLC | $26.51 | 2021 | |
| Boston Scientific Corporation | $26.36 | 2025 | Watchman Flx |
| Idorsia Pharmaceuticals US INC | $23.86 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $20.56 | 2022 | |
| Amarin Pharma, INC. | $17.12 | 2021 | |
| Dexcom, INC. | $16.62 | 2023 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $14.76 | 2021 | |
| Esperion Therapeutics, INC. | $13.95 | 2024 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $13.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauralee Sibiga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.